A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants

NCT07286370 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

537

Enrollment

INDUSTRY

Sponsor class

Conditions

Salmonella Infections

Interventions

BIOLOGICAL: Low dose of iNTS-TCV
BIOLOGICAL: Full dose of iNTS-TCV
BIOLOGICAL: TYPHIBEV
COMBINATION_PRODUCT: Prevenar 13
COMBINATION_PRODUCT: Nimenrix
DRUG: Saline

Sponsor

GlaxoSmithKline